ADVANCE FOR WEDNESDAY NOV 18; graphic shows market share for leading vaccine manufacturers
FILE - In this undated photo provided by Sanofi Pasteur, technicians perform production operations during a dry run at the company's influenza manufacturing facility in Swiftwater, Pa. Long seen as a sleepy, low-profit niche in the drug industry, this year investment in partnerships and other deals to develop and manufacture in vaccines is on a tear, seen as a crucial new path to growth. (AP Photo/Sanofi Pasteur, David W. Coulter) NO SALES
FILE - In this undated photo provided by Sanofi Pasteur, technicians perform production operations during a dry run at the company's influenza manufacturing facility in Swiftwater, Pa. Long seen as a sleepy, low-profit niche in the drug industry, this year investment in partnerships and other deals to develop and manufacture in vaccines is on a tear, seen as a crucial new path to growth. (AP Photo/Sanofi Pasteur, David W. Coulter) NO SALES
FILE - In this Oct. 19, 2009 file photo, a laboratory technician is seen at a Sanofi-Pasteur production plant manufacturing Panenza, a vaccine for the H1N1 flu virus, in Val-de-Reuil, western Paris. Long seen as a sleepy, low-profit niche in the drug industry, this year investment in partnerships and other deals to develop and manufacture in vaccines is on a tear, seen as a crucial new path to growth. (AP Photo/Jacques Brinon, File)
FILE - In this Oct. 19, 2009 file photo, a laboratory technician is seen at a Sanofi-Pasteur production plant manufacturing Panenza, a vaccine for the H1N1 flu virus, in Val-de-Reuil, western Paris. Long seen as a sleepy, low-profit niche in the drug industry, this year investment in partnerships and other deals to develop and manufacture in vaccines is on a tear, seen as a crucial new path to growth. (AP Photo/Jacques Brinon, File)
Leave your notes and wishes for the deployed Wyomingites.
© Copyright 2009, trib.com, Casper, WY | Terms of Service and Privacy Policy
